Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 21, 2010

Roche Expands Agreement with b3 bio to Include Therapeutic Technologies

  • b3 bio signed an agreement with Roche to source and develop innovative early-stage technologies that could result in potential therapeutic benefits. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as provide development funds.

    b3 bio and Roche started their partnership in July, 2008. The initial arrangement focused on the development of delivery systems for a range of drug candidates and diagnostic cargos.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »